Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Zuo, Jianmin; Dowell, Alexander C.; Pearce, Hayden; Verma, Kriti; Long, Heather M.; Begum, Jusnara; Aiano, Felicity; Amin-Chowdhury, Zahin; Höschler, Katja; Brooks, Tim; Taylor, Stephen; Hewson, Jacqueline; Hallis, Bassam; Stapley, Lorrain; Borrow, Raymond; Linley, Ezra; Ahmad, Shazaad; Parker, Benjamin; Horsley, Alex; Amirthalingam, Gayatri; Brown, Kevin E.; Ramsay, Mary; Ladhani, Shamez; Moss, Paul

doi:10.1038/s41590-021-00902-8

Cited by 342 publications

(309 citation statements)

References 41 publications

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…Older adults make up the most vulnerable population to COVID-19 and therefore have been prioritized for vaccination 19 . We found similar age-dependent decline in FRNT50 titers against each lineage in our study (Figures 1F-H).…”

Section: Mainmentioning

confidence: 99%

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum

Bates

Leier

Lyski

et al. 2021

Preprint

View full text Add to dashboard Cite

We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced levels of neutralization by vaccinated and convalescent sera. Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.

show abstract

Section: Mainmentioning

confidence: 99%

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum

Bates

Leier

Lyski

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…22 ). An effective T cell response might not only be important for recovery from COVID-19 but might also be important for long-term immunity 12,14,23 . Such T cell responses were shown to persist for up to 11 years after SARS-CoV-1 infection 24 , and T cells can provide substantial protection in animal models of highly pathogenic coronavirus infection 25 .…”

mentioning

confidence: 99%

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Ward

Gobeil

Séguin

et al. 2021

Nat Med

246

276

View full text Add to dashboard Cite

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18–55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 μg, 7.5 μg, and 15 μg) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-γ and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate.

show abstract

“…Although several studies have reported that individuals develop robust SARS-CoV-2-specific memory T cell responses following natural infection [1][2][3][4][5] , whether these responses correlate with clinical or immunologic outcomes has remained unclear. In the current issue of Nature Immunology, Zuo et al 6 characterize the durability and diversity of memory T cell responses established after asymptomatic or mild COVID-19.…”

mentioning

confidence: 99%